No one has the Valeant act down quite like Endo. After a guidance-slashing reminiscent of the Canadian pharma’s, the Dublin drugmaker is now following up with asset-sale discussions.
Endo has held talks with private equity firms about potential divestments that could help cut down its $8 billion-plus mountain of debt, Reuters’ sources say. It’s been looking into several options, including an asset swap with another company–though discussions are still in the early stages.
Endo–whose CEO, Rajiv De Silva, previously served as the COO at Valeant–has long seemed to be following in the footsteps of its specialty pharma peer, piling up debt in its race to gobble up smaller companies.
But these days, that’s no longer a good thing. Valeant has gone from Wall Street darling to bottom-feeder as debt-default concerns and dismal sales have taken their toll, and its new CEO–Perrigo vet Joseph Papa–has touted potential asset sales as a way to pay down debt and reduce some of the complexity of Valeant’s business.
Endo, too, reported disappointing quarterly sales last month that forced it to lower its 2016 EPS and revenue benchmarks. Shareholders–as Valeant’s did after a similar takedown in March–bolted for the exits. Shares crashed by nearly 40% as management attributed the change to new rivals on the market, greater-than-expected generics price erosion and regulatory delays.
Now, it remains to be seen if asset sales can turn Endo’s performance around–though after last month’s events, some analysts may be hard to convince.
“Weak longer term outlook, drastically lowered guidance, and pushed out de-levering targets (4.6x leverage) are the key reasons we view the stock as toxic,” Mizuho analyst Irina Koffler wrote after the guidance adjustments, adding that she “can’t see a reason” to own Endo shares.
By Carly Helfand
Source: Fierce Pharma
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.
